EUVIMEDEUVIMED entdecken
Crossref

Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer

Lauren Tagliaferro Epler, Joel W. Neal

AME Clinical Trials Review · 2024

DOI: 10.21037/actr-23-36 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Lauren Tagliaferro Epler und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Epler, L. T., & Neal, J. W. (2024). Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-36

Vancouver

Epler LT, Neal JW. Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-36

BibTeX
@article{Epler2024,
  author = {Epler, Lauren Tagliaferro and Neal, Joel W.},
  title = {Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer},
  journal = {AME Clinical Trials Review},
  year = {2024},
  doi = {10.21037/actr-23-36}
}
Kostenlos starten →